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INTRODUCTION
Since the discovery of the biological clock, the concept of treating cancer according to biological 
rhythms, here termed cancer chronotherapy, has rapidly evolved. Its fundamental aim is to improve 
the efficacy of drugs and to minimize adverse effects by administering chemotherapeutic drugs at 
the appropriate time-of-day. In the last two decades, several experimental and clinical studies have 
reported positive associations between the circadian clock and drug response in cancer patients. 
However, the lack of mechanistic insights into critical, deterministic clock-controlled genetic, and 
metabolic variations between and within individual cancer patients continue to cast a shadow 
on the potential benefits cancer chronotherapy may provide. Here, we provide first a simplified 
overview on our biological clocks and how our life-style induces complex biochemical reactions 
and genetic interactions. Next, we summarize how these reactions directly and indirectly modulate 
the effectiveness and toxicity of oncological drug treatments. Since cytotoxic chemotherapy 
represents the most common and affordable of cancer treatments, a case should be made that 
we need to ensure these treatments are used in the best possible manner. Thus, we list current 
challenges and future directions toward that goal.
INTERVIEW WITH PROFESSOR FRANCIS ALBERT LÉVI, 
CLINICAL PROFESSOR OF BIOMEDICINE AT THE UNIVERSITY 
OF WARWICK MEDICAL SCHOOL, EMBO | EMBL SYMPOSIUM: 
BIOLOGICAL OSCILLATORS: DESIGN, MECHANISM, FUNCTION
Professor Francis Albert Lévi is Clinical Professor of Biomedicine – Medical Oncology at the 
University of Warwick Medical School and Honorary Consultant at the Cancer Center, University 
Hospital Birmingham Queen Elisabeth. His team aims to streamline basic and clinical research 
on biological clocks, drugs, and diseases to promote the integration of chronotherapy into drug 
development and daily medical practice. The ultimate goal of Prof. Francis Lévi and his team is to 
predict and prevent diseases through the fine-tuning of our biological rhythms.
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WHAT IS CURRENTLY THE 
MAIN CHALLENGE IN CANCER 
CHRONOTHERAPY?
“The scientific and technological challenges are to adjust 
chronotherapy to the circadian clock in both healthy and tumor 
tissues of cancer patients. To do this, we need to stratify cancer 
patients according to how their circadian clocks are working, and 
to identify the optimal timing for the delivery of chronotherapy 
accordingly. This means that we would need to develop five to ten 
Phase I-II and III clinical trials with strong translational components 
and have them funded through long-term investment strategies. In 
parallel, we need Regulatory Agencies to make the recording of time, 
day, and month of treatments and sample collections a mandatory 
information during drug trials, and convince pharmaceutical 
companies that drug development could greatly benefit from 
considering timing issues during preclinical and early clinical 
testing. This could help us obtain the clinical data that we need in 
order to evaluate the potential benefit of therapeutic strategies.”
HOW COULD BASIC RESEARCH HELP 
ADVANCE THE FIELD?
“Generally, basic chronopharmacology research involves a 
standardized, systematic approach when studying physiology 
and pharmacology in animals or cultured cells. This allows us 
to generate a substantial amount of quantitative information on 
time-dependent drug pharmacology, efficacy, and toxicity. We 
need mathematical approaches to systematically map cancer 
chronopharmacology mechanisms in cellular models with 
synchronized clocks. Next, we need the ability to adjust these 
models established in rodent models in healthy volunteers 
and in cancer patients. Thus, a systems chronopharmacology 
approach going from cells to whole organisms would appear 
to be the currently best available option for modern cancer 
chronotherapeutics. In addition, novel approaches aiming to 
enhance the robustness of the circadian clocks in the host or 
in the cancer also represent a way forward, as illustrated by the 
recent findings of Dr. Panda and his team (Mure et al., 2018). 
However, as suggested in their studies, primates and mice share 
very few common genes of which display rhythmical expression. 
This finding highlights the diversity of the molecular clock across 
species. Thus, the design and evaluation of chrono-modulatory 
treatments in animal models calls for additional attention.”
WHAT IS THE OUTLOOK ON CANCER 
CHRONOTHERAPY?
“With our constantly expanding mechanistic understanding 
of the molecular clock and its dynamic interaction with many 
metabolites, with the cell cycle and with cell survival pathways, 
as well as the refinement of mathematical models applied to 
systems-level data, I believe we will soon be able to change the 
landscape of chronotherapy. I look forward to seeing you, along 
with all other young scientists, working further and deeper on 
the biological clock in order to achieve this goal.”
RATIONALE
Despite immense advances in cancer research and the development 
of novel therapies in oncology over the past decades, cancer 
remains one of the leading causes of death worldwide. According 
to the World Health Organization’s (WHO) estimates of cancer 
incidence and mortality of all ages and both sexes presented for 
2012, there were c.a. 1.8 million new cases and 1.6 million deaths 
of lung cancer alone. Therapeutic treatment options for many of 
these cancers are limiting, despite of intense research activities 
and many technological and biological innovations. Indeed, 
from a standpoint of pharmaceutical development, recent 
analysis on the development of novel oncologic drugs for breast, 
colorectal, and nonsmall cell lung cancer show very high attrition 
rates. Between 1979 and 2014 (Nixon et al., 2017), attrition rate 
for new cancer therapies has been significantly high. Over 80% 
for drug classes including cytotoxic chemotherapeutic reagents 
and cancer immunomodulators failed to advance to later stages 
in clinical trial. According to this analysis, oncological drugs 
are more likely to fail in late stage clinical trials (transition from 
Phase II to III) compared to other drugs. The authors concluded 
that adjusting and refining the design of early stage clinical trials 
may aid in the successful selection of drugs in later and more 
expensive stages of drug development (Nixon et al., 2017).
An additional, important aspect – and possibly the real, 
“biological” crux of the matter at hand – is the distinct variation 
in drug responses between individual patients. This highlights 
the urgency and a need to understand the variables that exist 
between individuals in order to improve the current status of 
cancer treatment. Such knowledge could clearly benefit the 
testing and selection of potential drugs for further development 
and clinical testing. From this standpoint, the distinct genetic and 
epigenetic make-up of individuals contributes greatly to individual 
variation. Increasingly, we will therefore likely see basket trials 
in oncology, for example, where patients are stratified based on 
genetic/genomic markers, such as the absence of a particular 
tumor suppressor gene, for example, rather than the etiology of 
the tumor itself. Moreover, emerging evidence in chronobiology 
strongly supports the intertwining relationship between our cyclic 
environment, behavior, and physiology, as well as the influence on 
the biochemical and genetic activity of our tissues and organs.
The question then is how we can exploit our fundamental 
knowledge of environmental and metabolic cycles to improve 
cancer treatment? While many factors come into play, this brief 
perspective focuses on how an appreciation for circadian biology 
might improve on the clinical use of global care standards in 
cancer chemotherapy.
LAYING THE FOUNDATION FOR CANCER 
CHRONOTHERAPY
Over half a century ago, Dr. Mauricio Garcia-Sainz and Dr. Franz 
Halberg identified, through computational analyses, a 24-h mitotic 
rhythmicity in human mammary but not squamous and basal 
cell cancer biopsy samples obtained before or after radiotherapy 
(Garcia-Sainz and Halberg, 1966). They were able to distinguish 
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the variance as rhythmicity <20 h and observed a population 
reduction of such ultradian rhythmicity in samples obtained 
after radiotherapy. This discovery established chronopathology 
and opened up the conceptual possibility for the development 
of chrono-modulated therapies. However, the potential of this 
information did not fully blossom until the identification of the first 
clock gene by Michael W. Young, Michael Rosbash, and Jeffrey C. 
Hall in the 1990’s. Since then, Prof. Francis Albert Lévi, a clinician 
and scientist, his team, as well as others in the field have been 
actively researching and promoting the concept of targeting the 
circadian clock to improve current cancer treatments* (see a short 
interview with Prof. Lévi on page XX of this perspective). However, 
to date, cancer chronotherapy faces numerous challenges, some 
of which we will discuss in this article. In the following sections, 
we will provide a simplified summary of the circadian clock, how 
circadian regulatory network extends into chemotherapeutics, and 
summarize up-to-date implications of chronobiology in cancer 
therapy *https://warwick.ac.uk/fac/sci/med/research/biomedical/
labs/chronotherapy/about/.
LIFE EVOLVED IN SYNC WITH THE 
ENVIRONMENT
Due to the Earth’s rotation, virtually all life has adapted and 
evolved an approximately 24-h biological rhythmicity in order 
to anticipate periodic changes in our environment, such as 
light, temperature, and food availability. This behavioral and 
physiological rhythmicity driven by natural sunlight is termed 
the circadian clock (circa diem). One tenable theory is that 
organisms evolved to store and utilize energy in synchrony 
with its environments. Thus, most fundamental biological 
processes such as cell metabolism and growth are thought to 
follow a daily circa 24-h oscillation [for a review, see (Takahashi 
2016)]. However, a recent metabolomic analysis has elegantly 
demonstrated the existence of other (non-24-h) rhythmicity 
and periodicity as well (Krishnaiah et al., 2017). Overall, cellular 
processes are thus greatly subjected to cyclic environmental 
cues, responses, and behaviors.
LIGHT ENTRAINS THE CENTRAL CLOCK
In animals, the eye possesses the ability to sense light. Upon 
exposure to light, complex signals are sent through the 
retinohypothalamic tract and subsequently processed in 
the suprachiasmatic nucleus (SCN). In the SCN, a relatively 
small population of specialized cells regulates the synthesis 
of the hormone melatonin by the pineal gland. The result of 
fluctuating melatonin levels, in turn, triggers the “resetting” 
of peripheral clocks, such as the liver and kidneys. These 
seemingly simple neurochemical and hormonal processes 
drive the most overt biological rhythmicity, the sleep-wake 
cycle, and is regarded as the central clock [for a review, 
see (Korf and von Gall, 2013)]. However, the molecular 
mechanism of how melatonin and likely other hormones 
synchronize peripheral tissues remains unclear.
NUTRIENTS REGULATE PERIPHERAL 
CLOCKS
While natural cyclic exposure to light remains the key driver 
of our biological clocks, nutrients have emerged as another key 
factor in the synchrony of peripheral clocks. Liver, regarded as the 
metabolic hub, has been extensively characterized as a circadian 
organ (Koike et al., 2012). Transcriptomic and proteomic 
analyses on mice liver demonstrate the diurnal transcriptional 
and post-translational regulation of discrete cellular processes, 
which range from glucose and fatty acid metabolism to the cell 
cycle and autophagy (Robles et al., 2016; Wang et al., 2018). 
In agreement, several clinical studies have reported circadian 
rhythmicity in glucose, lipid and energy metabolism, such as 
insulin sensitivity and secretion, cholesterol synthesis, and 
fat oxidation (Poggiogalle et al., 2018). These findings further 
strengthen the concept of multiple cellular processes being under 
the direct and indirect influence of our environment, nutrition, 
behavior, and metabolism.
THE MOLECULAR CLOCK DRIVES 
TRANSCRIPTIONAL RHYTHMICITY
At the cellular level, neurochemical and hormonal cues induced 
by light and nutrients prompt the resetting of the molecular clock. 
However, the molecular clock is governed by several interlocking 
transcription and translation feedback loops (TTFLs), which 
proceeds for a long time even in the absence of external cues. 
A recent, groundbreaking circadian transcriptomics study in 
the olive baboon (Papio anubis) revealed over 80% of protein-
coding genes displayed a daily oscillation pattern in more than 
60 examined tissues (Mure et al., 2018). The majority of cycling 
genes were mainly ubiquitously expressed genes, which are often 
involved in fundamental cellular processes, such as circadian 
rhythmicity, DNA replication, DNA repair, amino-sugar 
metabolism, and oxidative phosphorylation (Mure et al., 2018).
To conclude, the biochemical and genetic response of a 
metazoan organism is influenced not only by our predetermined 
genetic and epigenetic make-up; but also by a plethora of ever-
changing external stimuli, including light and nutrients. Thus, 
in addition to well-studied genetic (Kandoth et al., 2013) and 
metabolic alterations (DeNicola and Cantley 2015) in cancer, we 
must now take into account both “clock alterations” and clock 
regulatory genetic and metabolic networks. Only in combination, 
will we potentially succeed in profiling cancer subtypes and 
strategizing treatments. In the following section, we will present 
our case on cancer chronotherapy and up-to-date findings on the 
relationship between the clock, cancer, and chemotherapeutics.
CIRCADIAN CLOCK FUNCTION 
INFLUENCES CANCER AND VICE-VERSA
Several recent findings indicate that there is a correlation 
between the circadian clock and the etiology of cancer. One 
bioinformatic study reported that clock genes in human tumor 
samples have altered gene expression profiles in comparison to 
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normal, adjacent tissues (Ye et al., 2018). To no surprise, they 
also found a correlation between clock gene expression and 
anticancer drug sensitivity in cancer cell lines (Ye et al., 2018). 
To support this, a number of experimental and clinical studies 
have reported a negative correlation between clock disruption 
during and/or after treatment with survival rate in cancer 
animal models and patients (Sephton et  al., 2013; Lévi et al., 
2014; Papagiannakopoulos et al., 2016). These findings indicate 
a dysfunctional or functional clock may serve as an indicator 
for the outcome of cancer progression and treatment response. 
However, circadian modulated anticancer drug response and 
the potential effect of our environment and behavior on cancer 
development lack well-defined molecular insights necessary 
to comprehend and exploit the clock for common cancer 
treatments. In the following paragraphs, we summarize state-
of-the-art findings in explaining how the circadian clock may 
improve the current status of cancer chemotherapy.
CYTOTOXIC CHEMOTHERAPY AS THE 
GLOBAL STANDARD OF CARE
There are various approaches targeted at treating cancer. Notably, 
in recent years, immunotherapeutic approaches have shown great 
promise and interest in the research and clinical community. 
Nevertheless, conventional chemotherapy, regardless whether 
administered as induction, combined, consolidation, or through 
other therapeutic strategies, remains one of the most broadly used 
and affordable treatments following surgical resection of tumor 
tissue. Despite current knowledge on how, for example, platinum-
based and similar chemotherapeutic drugs function, debilitating 
adverse effects resulting from severe damage to normal and 
healthy tissues limits the dosing of drugs and treatment duration 
(Tacar et al., 2012; Dasari and Bernard Tchounwou 2014). Using 
chemotherapeutic drugs at suboptimal doses and treatment 
duration, in turn, provides space for the cancer to develop drug 
resistance. Cancer therapy using chemotherapeutic agents thus 
persistently faces the major challenge of relapse. In the following, 
we summarize how the clock regulates the DNA damage repair 
machinery targeted by cytotoxic chemotherapeutical drugs, drug 
metabolism, and potentially drug resistance in cancer.
THE MOLECULAR CLOCK REGULATES 
THE DNA REPAIR MACHINERY
Conventional chemotherapy targets cells with enhanced 
proliferation rates and/or an impaired DNA repair machinery 
to achieve elimination of cancerous cells (Corrie, 2008). The 
circadian clock regulates these key hallmarks of cancer of which 
includes cell proliferation, metabolism, and genome stability [for 
extensive reviews, see (Sancar et al., 2010; Masri et al., 2013; Panda, 
2016)]. For example, cisplatin, a widely used and well-established 
chemotherapeutic drug in the treatment of numerous human 
cancers, exerts its function by crosslinking purine bases on DNA, 
causing bulky lesions. These bulky lesions interfere with DNA 
replication and overwhelm the DNA repair machinery, which 
generally results in cell death (for a review, see (Dasari & Bernard 
Tchounwou 2014)). These bulky DNA adducts are typically 
sensed and resolved by the nucleotide excision repair (NER) 
pathway. The activity of one particular key DNA repair protein, 
xeroderma pigmentosum A (XPA), was shown to be under direct 
circadian control in vivo (Kang et al., 2009; Kang et al., 2010). 
This knowledge strengthens the notion of timed drug (such as 
cisplatin) administration in accordance to the circadian “trough” of 
the targeted cell process (in this case, NER repair machinery) to 
increase drug efficacy.
DRUG RESISTANCE EMERGES OUT OF 
CELL MECHANISMS UNDER CIRCADIAN 
CONTROL
Cancer is a highly heterogeneous disease, rendering it a 
challenge to target and treat, as the genome rapidly evolves and 
resistance mechanisms arise albeit the simplicity of “timely” 
targeting. There are several proposed mechanisms of resistance 
to chemotherapy. Beside suboptimal drug dosage and treatment 
duration, this includes changes in the cellular uptake and efflux 
of the chemotherapeutic agent, increased drug metabolism 
and elimination, as well as enhanced DNA repair machineries, 
mechanisms, which suppress tumor cell death (Mansoori et al., 
2017). These resistance mechanisms emerge from processes that 
are controlled by the circadian clock (Sancar et al., 2010; Dallmann 
et al., 2014; Dallmann et al., 2016). Thus far, clinical studies have 
shown that several adverse effects experienced by cancer patients 
taking cisplatin-based chemotherapy decreases when cisplatin is 
applied in a chrono-modulated context (Li et al., 2015; Zhang et al., 
2017). The results and outcomes of these studies indicate that the 
proper timing of drug administration reduces cisplatin-induced 
adverse effects in patients. Chronotherapy may thus potentially 
enable substantial increases in the maximally tolerated dose. This 
raises the possibility that more effective toxicity to the tumor 
cells could be achieved, providing potentially a higher selectivity 
relative to the toxic effect of chemotherapy on normal cells.
In sum, the clock regulates the fundamental cell processes, 
which are often the targeted machinery of cytotoxic anticancer 
drugs. The clock also modulates the absorption, metabolism, and 
elimination of these drugs. In combination, chrono-modulated 
drug administration provides the potential to optimize the 
dosage of drugs and duration of treatments to efficiently eliminate 
highly proliferative cancerous cells while reducing limiting 
adverse effects to circumvent drug resistance. The potential for 
chronotherapy thus arises out of the physiological link between 
the cytotoxic cancer agents and molecular processes that respond 
to these agents on an organismic and cellular level.
CURRENT CHALLENGES AND 
FUTURE DIRECTIONS IN CANCER 
CHRONOTHERAPY
Several studies report clear changes in the effectiveness of cancer 
chronotherapy. However, significant interpatient variability 
persistently poses a major challenge for cancer chronotherapy 
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to gain statistical power (Ballesta et al., 2017). Giacchetti and 
colleagues conducted a comparative meta-analysis on conventional 
and chrono-modulated chemotherapeutic treatments in 842 
patients with metastatic colorectal cancer from three international 
randomized trials (Giacchetti et al., 2012). They found improved 
tumor response rate and overall survival, as compared to 
conventional chemotherapy in male patients by +3.3 months. 
Unexpectedly, the overall survival of female patients decreased by 
1.8 months (Giacchetti et al., 2012). One pilot study involving 55 
healthy people and 12 cancer patients found significant sex- and 
age-related variations in the coordination of individual circadian 
clocks as well (Komarzynski et al., 2018). These critical findings 
underscore the relevance of sex and age for cancer chronotherapy 
and require further investigations on their respective impacts for 
the scheduling of chronotherapy. Such variations likely stem from 
and result in the challenges listed below.
There are at least three challenges faced by cancer 
chronotherapy. These include:
 1. There is insufficient mechanistic insight at the level of basic 
research of how cancer and chemotherapeutic drugs affect the 
molecular clock and vice versa. This hampers the design of 
appropriate chrono-modulated clinical trials.
In the last decade, tremendous effort has been put into 
deciphering the structure, function, and regulatory network of 
the molecular clock and its core components. While the field is 
rapidly gaining new insights on these fundamental biological 
questions, we have yet directly addressed the impact of the 
clock and metabolic environment on cytotoxic drug sensitivity 
in a systematic manner. Thus, in our opinion, the field requires 
a systematic high-throughput cell (organelle)-based screening 
capability on the circadian-dependent effects of chemotherapeutic 
cytotoxicity in both model cancer and primary cell lines. This 
would help confer novel mechanistic information. Ultimately, 
such information could provide valuable data to generate unique 
combinatorial (cancer, drug, and clock) profiles which may serve 
as guidelines clinical trial designs.
 2. In clinical research, large variations among patients’ 
clocks can alter the statistical power of trials comparing 
chronotherapy to conventional treatment in patients with 
varying chronotypes (circadian clock).
Cancer profiling is under constant refinement from tumor 
localization, cell morphology, and cell surface biomarkers 
to genetic and epigenetic aberrations. We now must also 
acknowledge that the variation extends to our biological clocks. 
The design of chrono-modulated chemotherapy may benefit 
immensely from compulsory documentation of patient routines 
including sleep/wake cycles, activity, metabolic profile, and drug 
administration in all related drug trials. While this is of course 
a great challenge in terms of data gathering and analysis, the 
European Medicines Agency (EMA) and its nearing release of the 
EMA Clinical Trial Information System (CTIS) with uniformed 
regulations and absolute transparency will aid us in moving 
towards an improved era of personalized and precise medicine 
tailored to individual chronotypes.
      
Making chronotyping simple and easy   
Some wear it for fashion; some wear it for health.
Regardless, smart watches, apps (Gill and Panda 2015, 
https://mycircadianclock.org/) or other digital devices 
have the ability of recording valuable information of our 
cyclic behavior, such as when we sleep, how we sleep, 
and when and how we eat and exercise. By combining 
a given patient’s “digital” chrono-data with “biological” 
chrono-data, such as biopsies and/or blood samples, 
clinicians could then start to successfully chronotype 
individual patients and strategize cancer treatments 
accordingly. Applying such routines to clinical trials 
could help stratify patients and the results of the 
effectiveness of particular pharmacological therapies. 
 
 3. Pharmaceutical companies should be incentivized to invest 
in (re-)examining the time-dependent efficacy and toxicity of 
chemotherapeutic drugs, or to design clock-based drugs.
As suggested earlier (Nixon et al., 2017), the adjustment and 
refinement of early stage clinical trial design could permit a 
higher success rate in anticancer drug development. To put this 
into perspective, it costs on average a striking $2.6 billion USD 
to develop a drug (DiMasi et al., 2016). Considering the attrition 
rate of 80%, chronotherapeutic approaches could lead to the 
development of effective new anti-cancer drugs or improved 
FIGURE 1 | Exploiting the circadian clock for improved cancer therapy. We 
are exposed to ever-changing light, temperatures, and nutrients on a daily 
basis. In response to these Cyclic Stimuli, our bodies modulate a wide range of 
physiological and cellular processes in an oscillatory manner (Chronobiology). 
Since chronobiology is a complex physiological phenomenon, it is currently 
not greatly considered as a factor in the research and development of novel 
anticancer drugs, nor in clinical trials. Nonetheless, recent studies have 
reported correlations between the circadian clock, cancer and therapy 
response. Giacchetti et al., 2012; Sephton et al., 2013; Lévi et al., 2014; 
Papagiannakopoulos et al., 2016; Ye et al., 2018. We suggest that an in-depth 
understanding of circadian mechanisms from single tissue types to entire 
systems, could potentially allow us to stratify individual patients not only by 
genomic and genetic aberrations in their tumors, but also by clock functions 
(Chronotype). this could be of great benefit and improve cancer therapies.
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dosing regimens. Pharmaceutical companies should take into 
account the effect of the clock and recognize the potential in 
re-examining drugs to increase not only the therapeutic value 
of approved drugs, but also re-evaluate new chemical entities.
In conclusion, these interlinking challenges require 
collaborative efforts between basic science and medicine, clinicians, 
regulatory authorities, and pharmaceutical companies in order to 
obtain mechanistic insights and clinical statistics that would help 
shed light on how a given cancer affects the clock and vice versa, 
how a given oncotherapy affects the clock, and what other factors, 
such as our lifestyle and environment (personal chronotypes), 
can affect the clock and treatment responses. The landscape of 
chronotherapy is gradually maturing with the application of in silico 
pharmacology (Ekins et al., 2007), clinical big data (Mayo et al., 
2017; Singh et al., 2018), in vitro pharmacology, and mathematical 
modeling (Dulong et al., 2015) to help expand our knowledge of 
the molecular clock and its relevance to human disease, consistent 
with the important trend toward personalized medicine. Here, we 
have analyzed and explored the case for chronotherapy as an option 
to improve the effectiveness of existing and future cytotoxic cancer 
therapies. A better appreciation for this underlying fundamental 
biological phenomenon and its potential for chronotherapy could 
benefit many cancer patients worldwide (Figure 1).
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